Gene · 7014
NIH grants2,127
NIH grants whose papers are about the gene, through NIH's grant-paper links.
161 to 180 of 2,127
Download this page as JSON| Grant | Title | TERF2 papers | Newest fiscal year |
|---|---|---|---|
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 1 | 2025 |
| R01AG068937 | Social Circumstances and Epigenomics Promoting Health in Three Countries | 1 | 2025 |
| R01AG071707 | An integrated exercise and bladder training intervention to reduce falls in older women with urinary incontinence | 1 | 2025 |
| R01AG077324 | A nucleus-to-mitochondria nucleic acid-sensing pathway prevents bypass of age-associated proliferative boundaries | 1 | 2025 |
| R01AI039115 | Impact of RNAi and unisexual reproduction on Cryptococcus evolution, drug resistance, and pathogenesis | 1 | 2025 |
| R01AI125524 | Kinase Regulation of Nuclear Speckle Function and Splicing during Influenza Virus Infection | 1 | 2025 |
| R01AI163142 | A multipronged investigation of SARS-CoV-2 genome packaging | 1 | 2025 |
| R01AI179972 | Essential functions of Trypanosoma brucei RAP1 | 1 | 2025 |
| R01AR041398 | Novel Molecular Biomarkers of Bone Microarchitecture | 1 | 2025 |
| R01CA073764 | FEN1-mediated Okazaki fragment maturation and its deficiency in cancer | 1 | 2025 |
| R01CA129933 | Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor Cells | 1 | 2025 |
| R01CA140337 | Host pathways regulating Epstein-Barr virus-mediated B cell growth transformation | 1 | 2025 |
| R01CA177585 | Targeting MYC promoter G-quadruplex for MYC inhibition by Indenoisoquinolines | 1 | 2025 |
| R01CA198279 | Shaping DNA Damage Response Networks Via Histone H2A Variants | 1 | 2025 |
| R01CA237263 | DNA replication stress in cancer | 1 | 2025 |
| R01CA240290 | Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells | 1 | 2025 |
| R01CA244261 | Mechanistic characterization of the cell cycle-dependent DNA repair pathway- Resubmission | 1 | 2025 |
| R01CA248526 | Mechanisms of replication fork protection and recovery | 1 | 2025 |
| R01CA254036 | Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer | 1 | 2025 |
| R01CA256188 | Probing cytosolic nucleic acid sensing pathways in cancer | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7014/grants?page=9